Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.
Alloway
Rita
R
Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, OH, and California Institute of Renal Research, Sharp Memorial Hospital, San Diego, CA, USA.
Steinberg
Steven
S
Khalil
Kassem
K
Gourishankar
Sita
S
Miller
Joshua
J
Norman
Douglas
D
Hariharan
Sundaram
S
Pirsch
John
J
Matas
Arthur
A
Zaltzman
Jeffrey
J
Wisemandle
Kathleen
K
Fitzsimmons
William
W
First
M Roy
MR
D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D016559:Tacrolimus / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D007166:Immunosuppressive Agents; D016559:Tacrolimus